- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00351403
Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection
Individually Adapted Therapy Duration From 24 to 72 Weeks for the Treatment of a Chronic Hepatitis C Genotype 1 Infection With Peginterferon Alfa-2b Plus Ribavirin in Dependence of the Initial Concentration and the Decline of the HCV RNA
Patients with chronic hepatitis C genotype 1 virus infection are usually treated with Interferon alfa plus Ribavirin over 48 weeks. For some patients this might be too long, for others too short. An individually adapted therapy length from 24 to 72 weeks will be determined in dependence of the initial virus load and the time to HCV RNA negativity.
The primary objective is to compare the cumulative rate of the sustained viral response (SVR) of the patients with the individually adapted therapy duration to the SVR rates of a historic patient collective under the 48 week standard therapy.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Further objectives of this trial are:
To record the tolerance of the therapy with Peginterferon alfa-2b plus Ribavirin over 72 weeks inclusive the adverse reactions and the withdrawal rates.
To evaluate the biochemical response to the treatment (ALT values during and after the therapy) in comparison to the virological response to the treatment.
To evaluate the validity of the withdrawal rules of this trial at week 12 and 24 in comparison to the 2-log-rule and a qualitative detection of the HCV RNA at week 24 with a detection limit of 50 IU/ml.
To evaluate the impact of the HCV RNA concentration before the therapy, and the HCV kinetic during the therapy on the response to the treatment in the different groups.
To evaluate the impact of the serum concentration of Ribavirin on anaemia and the virological therapy response, as well as the dependence of the serum concentration of Ribavirin on the creatinine clearance in comparison to the body weight.
Type d'étude
Inscription (Anticipé)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
-
Berlin, Allemagne, 13353
- Charité, Campus Virchow-Klinikum
-
Berlin, Allemagne, 10969
- Hepatologische Schwerpunktpraxis
-
Hamburg, Allemagne, 20246
- Universitätsklinikum Hamburg-Eppendorf
-
-
Baden-Württemberg
-
Freiburg, Baden-Württemberg, Allemagne, 79106
- Medizinische Universitätsklinik Freiburg
-
Heidelberg, Baden-Württemberg, Allemagne, 69120
- Universitätsklinik Heidelberg
-
Ulm, Baden-Württemberg, Allemagne, 89081
- Universitatsklinikum Ulm
-
-
Bayern
-
Erlangen, Bayern, Allemagne, 91056
- Uniklinikum Erlangen
-
München, Bayern, Allemagne, 81675
- Technische Universität München
-
München, Bayern, Allemagne, 81377
- Klinikum Großhadern
-
Würzburg, Bayern, Allemagne, 97080
- Klinikum der Universität Würzburg
-
-
Hessen
-
Frankfurt, Hessen, Allemagne, 60590
- Klinikum der J.W.-Goethe-Universität
-
Frankfurt, Hessen, Allemagne, 60596
- Praxis für Innere Medizin
-
-
Niedersachsen
-
Hannover, Niedersachsen, Allemagne, 30625
- Medizinische Hochschule Hannover
-
-
Nordrhein-Westfalen
-
Bochum, Nordrhein-Westfalen, Allemagne, 44791
- St. Josef-Hospital
-
Dusseldorf, Nordrhein-Westfalen, Allemagne, 40237
- Gemeinschaftspraxis
-
Essen, Nordrhein-Westfalen, Allemagne, 45122
- Medizinische Universitäts-Klinik Essen
-
Köln, Nordrhein-Westfalen, Allemagne, 50924
- Universität zu Köln
-
-
Nordrhein.Westfalen
-
Aachen, Nordrhein.Westfalen, Allemagne, 52074
- Universitätsklinikum Aachen
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Allemagne, 55131
- Universitätsklinikum der J. Gutenberg Universität
-
-
Saarland
-
Homburg / Saar, Saarland, Allemagne, 66421
- Universitätsklinikum des Saarlandes
-
-
Sachsen
-
Leipzig, Sachsen, Allemagne, 04103
- Universitätsklinikum Leipzig
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Allemagne, 24105
- Christian-Albrechts-Universität zu Kiel
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients with a chronic HCV infection (HCV antibodies and HCV RNA positive)
- Presence of a HCV genotype 1 infection
- Presence of a compensated liver disease satisfying following hematological and biochemical minimum criteria: - Hemoglobin value >= 13 g/dl in men, >= 12 g/dl in women - Leukocytes >= 3.000/mm3 or neutrophile granulocytes > 1.500/mm3 - Thrombocytes > 80.000/mm3
- Total bilirubin in the normal range
- Albumin in the normal range
- Serum creatinine in the normal range THS in the normal range
- Exclusion of an autoimmune hepatitis
- Alpha-Fetoprotein in the normal range
- Negative HIV test
- Negativity of Hepatitis B surface antigens (Hbs-Ag)
- Normal or elevated ALT/GTP values at screening
- At known diabetes mellitus or hypertension an ophthalmologic examination must be performed
- Liver biopsy within the last 12 months must confirm the diagnoses of a chronic hepatitis
- A confirmation must be given that sexually active patients practice a save method of contraception during the therapy and 6 (women) to 7 (men) months after the therapy
Exclusion Criteria:
- Age < 18 years, > 70 years
- Previous treatment of hepatitis c with (Peg)Interferon alfa or (Peg)Interferon alfa/Ribavirin
- Patients with organ transplantations other than cornea or hair
- Infection with HCV genotype 2,3,4,5 or 6
- Pregnant or nursing women
- Any other reason for the liver disease than chronic hepatitis C
- Suspected hypersensitivity to Interferon, Peginterferon or Ribavirin
- Participation in a clinical trial or treatment with an investigational product 30 days before inclusion in this study
- Patients with any kind of hemoglobinopathy
- Documented liver disease in advanced state Liver cirrhosis Child B and C
- Each known and existing clinical conditions that might challenge the participation or completion of this clinical trial as depressions, psychosis, severe psychiatric diseases, suicide ideations CNS traumata or cramps which need medicamentous treatment
- Relevant cardiovascular dysfunctions in the last 6 months or patients with clinically relevant changes in the ECG
- Insufficiently adjusted diabetes mellitus
- Severe chronic lung diseases (as e.g. COPD)
- Immunologic diseases or autoimmune-diseases or any other disease which demand a longtime treatment with corticosteroids during this clinical trial
- Clinically relevant gout
- Abuse of drugs, alcohol or pharmaceuticals
- Patient with clinically relevant changes of the retina
- Missing ability or willingness to understand the purpose of this study or to give a written consent for participating in this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Individualized therapy
Lengh of therapy depends on time point when no HCV RNA is detectable in blood with Versant HCV Qualitative assay.
|
Rebetol 200 mg: applied as hard capsule
PegIntron (50/80/100/120/150 microgram): applied by injection
|
Autre: Historical control
48 week standard therapy
|
Rebetol 200 mg: applied as hard capsule
PegIntron (50/80/100/120/150 microgram): applied by injection
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
---|
Sustained viral response (HCV RNA negativity 24 weeks after end of treatment)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Christoph Sarrazin, MD, PhD, University Hospital, Saarland
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Infections par virus à ARN
- Maladies virales
- Infections transmissibles par le sang
- Maladies transmissibles
- Maladies du foie
- Infections à Flaviviridae
- Hépatite, virale, humaine
- Infections à entérovirus
- Infections à Picornaviridae
- Hépatite chronique
- Infections
- Hépatite
- Hépatite A
- Hépatite C
- Hépatite C chronique
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-infectieux
- Agents antiviraux
- Antimétabolites
- Ribavirine
- Peginterféron alfa-2b
Autres numéros d'identification d'étude
- INDIV-2
- 2006-000358-38 (Numéro EudraCT)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Hépatite C chronique
-
PfizerComplétéLeucémie, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) PositifFrance, États-Unis, Canada, Espagne, Tchéquie, Singapour, Thaïlande, Danemark, Norvège, Corée, République de, Finlande, Hongrie, Suède, Pays-Bas, Italie, Allemagne, Ukraine, Afrique du Sud, Taïwan, Australie, Belgique, Israël, Mexique, Pologn... et plus